Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH

21 February 2019

Inventiva Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis

18 February 2019

New results on lanifibranor to be presented at the International Liver Congress™ 2019

4 February 2019

Inventiva Announces Two Poster Presentations at the American College of Rheumatology Conference

10 October 2018

Inventiva advances in the development of lanifibranor with the achievement of three key milestones

30 August 2018

Inventiva’s lanifibranor found to have good safety profile following first assessment of carcinogenicity studies’ results

13 August 2018

Inventiva Announces Positive DSMB Reviews in both NASH and Systemic Sclerosis Phase IIb Trials with Lanifibranor

10 July 2018

Inventiva Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes

3 April 2018

Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors

28 March 2018

Inventiva’s paper on the discovery and synthesis of its panPPAR agonist lanifibranor accepted and published in the Journal of Medicinal Chemistry of the American Chemical Society

13 March 2018

Inventiva Announces Positive DSMB Review in Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor

4 January 2018

Inventiva’s Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor Completes Enrollment

17 October 2017

Inventiva’s IVA337 Given Generic Name “Lanifibranor” by the World Health Organization (WHO)

18 September 2017

Inventiva to Present New Data on IVA337 at the 15th International Workshop on Scleroderma Research in Pittsburgh, USA

27 July 2017

Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models

20 June 2017

Inventiva Announces Positive Results of 12 Month Primate Toxicity Study with IVA337

15 May 2017

Inventiva Announces Presentation of Preclinical Results on IVA337 in NASH at the International Liver Congress™ 2017 (EASL)

20 April 2017

Inventiva Hits Clinical Milestone with Enrollment of 100th Patient in IVA337 Phase 2b FASST Trial in Systemic Sclerosis (SSc)

10 April 2017

Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)

3 January 2017

Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress

25 February 2016

12